

# Osteoporosis International

## COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY

--Manuscript Draft--

<b>Manuscript Number:</b>	OSIN-D-13-00312R2
<b>Full Title:</b>	COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY
<b>Article Type:</b>	Original Article
<b>Abstract:</b>	<p><b>Purpose:</b> The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from antero-posterior spine DXA scans. The potential role of TBS for monitoring treatment response with bone active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.</p> <p><b>Methods:</b> Two patient groups with matched age, BMI, and baseline LS BMD, treated with either daily subcutaneous teriparatide (N=65) or quarterly intravenous IBN (N=122) during 2 years and with available LS BMD measurements at baseline and two years after treatment initiation were compared.</p> <p><b>Results:</b> Baseline characteristics (overall mean <math>\pm</math> SD) were similar between groups in terms of age, <math>67.9 \pm 7.4</math> years; body mass index, <math>23.8 \pm 3.8</math> kg/m<sup>2</sup>; BMD L1-L4, <math>0.741 \pm 0.100</math> g/cm<sup>2</sup> and TBS, <math>1.208 \pm 0.100</math>. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (<math>+7.6\% \pm 6.3</math> vs. <math>+2.9\% \pm 3.3</math> and <math>+4.3\% \pm 6.6</math> vs. <math>+0.3\% \pm 4.1</math>, respectively; <math>p &lt; 0.0001</math> for both). LS BMD and TBS were only weakly correlated at baseline (<math>r^2 = 0.04</math>) with no correlation between the changes in BMD and TBS over 24 months.</p> <p><b>Conclusions:</b> In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.</p> <p><b>KEY WORDS:</b> osteoporosis, parathyroid hormone, teriparatide, bone mineral density, trabecular bone score, treatment, open-label study</p>
<b>Corresponding Author:</b>	Kurt Lippuner, M.D. University Hospital and University of Berne Bern, SWITZERLAND
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	University Hospital and University of Berne
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Christoph Senn
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Christoph Senn Beatrice Günther Albrecht W Popp

	Romain Perrelet
	Didier Hans
	Kurt Lippuner, M.D.
<b>Order of Authors Secondary Information:</b>	
<b>Author Comments:</b>	<p>Dear Prof Seeman</p> <p>please find herewith the revised manuscript. We hope that it will be acceptable for publication in OI in its present form.</p> <p>With best regards, Kurt Lippuner</p>
<b>Response to Reviewers:</b>	<p>OSIN-D-13-00312R1</p> <p>"COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY"</p> <p>Reply to reviewers' comments:</p> <p>Thank you for having reviewed and commented our work. You will find our reply (bold fonts) to your questions / comments / suggestions (normal fonts) below. These reconcile with changes to the manuscript also highlighted in bold fonts directly in its text.</p> <p>Reviewer #1:</p> <p>The authors compared the effect of treatment for 2 years with Teriparatide (TPTD) or Ibandronate (IBN) on BMD lumbar spine and TBS (trabecular bone score) in 187 postmenopausal women with osteoporosis. The study was retrospective, non-randomised and open-label. The patients were matched for age, BMI, BMD and TBS but not for osteoporosis severity evaluated by previous fractures, previous BP-treatment and FRAX score. BMD and TBS were not able to discriminate patients with more severe osteoporosis from patients with less severe osteoporosis. Patients treated with TPTD responded with larger increases in BMD and TBS than the patients treated with IBN. There was no correlation between BMD and TBS at baseline or between the changes in the two parameters with treatment.</p> <p>Specific comments:</p> <p>Material and methods:</p> <p>p.6, l.9-: It should be stated that the study design is retrospective, non-randomised and open-label. It should be stated that study compares the effects of up to 2-years treatment with TPTD with 2-years treatment with IBN.</p> <p>The first paragraph has been amended as follows: "The study was conducted at the Department of Osteoporosis of the University Hospital of Berne, Switzerland as an open-label, retrospective, non-randomised, treatment-controlled study comparing the effects of an up to 2-year treatment with subcutaneous teriparatide (Forsteo®, Eli Lilly, USA) vs. a 2-year treatment with intravenous IBN (Bonviva®, Roche, Switzerland) on LS BMD and TBS in two groups of postmenopausal women with osteoporosis matched for age, BMI, and LS BMD."</p> <p>Furthermore, if DXA at baseline and after two years only was available in 65 and 122 patients in the two groups, respectively and this is one of the inclusion criteria, then only these patients can be included in the study. The authors may have evaluated 70 and 140 patients, respectively, to include these patients. This needs clarification in the manuscript.</p> <p>To avoid any confusion, the word "eligible" was replaced by "evaluated" in the study population section of the methods. In addition, the following sentence was added as a final sentence in the same paragraph: "Only women with evaluable DXA scans for both LS BMD and TBS at baseline and after two years in the teriparatide and the</p>

ibandronate groups, respectively, were included in the analysis.”

Figure 1: If TPTD patients were only treated for on average 22.9 months with TPTD, information about the follow-up treatment should be provided.

The legend of figure 1 was amended as follows: “Percent change in lumbar spine BMD and TBS at month 24 after treatment with teriparatide (22.9 months) and ibandronate (24 months).

Mean values  $\pm$  standard deviation

p values above the bars refer to significance vs. baseline.”

In addition, the following clarifying sentence was added to the methods section / study population and treatment schemes:

“The reimbursed duration of treatment with teriparatide was increased from 18 to 24 months during the course of the study. As a consequence, one sixth of the patients treated with teriparatide were treated during 18 months followed by an intravenous infusion of zoledronate 5mg, the other five sixths were on teriparatide during 24 months.”

Results:

p.9 and figure 1: As the interesting results are the changes and the variation in the changes in the two groups of patients and not the group mean changes, the changes should be presented as meanSD in the text as well as in the figure. The changes as the two hip sites mentioned in table 1 should also be provided.

As requested, the SEM on figure 1 have been replaced by SD, consistent with the text. Regarding the hip results, the aim of the study was to have a head to head skeletal site matched comparison between spine BMD and TBS for the two treatments. We feel that providing hip results in this paper would dilute the message, even more so if results were to be added to figure 1. Thus, we suggest not mentioning the hip results in the manuscript. For your personal information the total hip and FN BMD increased by  $+0.12 \pm 4.5\%$  and  $+0.44 \pm 5.0\%$  for the PTH group and by  $+2.5 \pm 3.5\%$  and  $+0.5 \pm 4.5\%$  for the IBN group, respectively. As already stated, we recommend not adding this information to the manuscript but may of course do so on your request.

Table 2: As LSCs are 2.49% and 3.10% it is clear what above and below LSC mean, but not what within LSC means?

Within LSC means, all values comprised between  $+2.49$  and  $-2.49\%$  and between  $+3.10$  and  $-3.10\%$  for spine BMD and TBS, respectively. We have clarified this confusing point by adding a corresponding footnote to table 2.

Reviewer #2:

The Authors have replied to my comments. I have no further remarks.

Thank you for your comments and suggestions which greatly contributed to improving the quality of our work.

COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE  
MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL  
WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY

Christoph Senn<sup>1</sup>, Beatrice Günther<sup>1</sup>, Albrecht W Popp<sup>1</sup>, Romain Perrelet<sup>1</sup>, Didier Hans<sup>2\*</sup>, Kurt  
Lippuner<sup>1\*</sup>

<sup>1</sup> Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne,  
3010 Berne, Switzerland

<sup>2</sup> Center of Bone Disease, Bone and Joint Department, Lausanne University Hospital, Avenue  
Pierre Decker 4, 1011 Lausanne VD, Switzerland

\* co-directed equally the TBS study

Corresponding author:

Kurt Lippuner, M.D.  
Chairman and Head  
Department of Osteoporosis  
Inselspital, Berne University Hospital  
and University of Berne  
CH-3010 Berne  
Switzerland  
phone +41 31 632 31 28  
fax +41 31 632 03 28  
email kurt.lippuner@insel.ch

## ABSTRACT (words = 246)

**Purpose:** The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from antero-posterior spine DXA scans. The potential role of TBS for monitoring treatment response with bone active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

**Methods:** Two patient groups with matched age, BMI, and baseline LS BMD, treated with either daily subcutaneous teriparatide (N=65) or quarterly intravenous IBN (N=122) during 2 years and with available LS BMD measurements at baseline and two years after treatment initiation were compared.

**Results:** Baseline characteristics (overall mean  $\pm$  SD) were similar between groups in terms of age,  $67.9 \pm 7.4$  years; body mass index,  $23.8 \pm 3.8$  kg/m<sup>2</sup>; BMD L1-L4,  $0.741 \pm 0.100$  g/cm<sup>2</sup> and TBS,  $1.208 \pm 0.100$ . Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN ( $+7.6\% \pm 6.3$  vs.  $+2.9\% \pm 3.3$  and  $+4.3\% \pm 6.6$  vs.  $+0.3\% \pm 4.1$ , respectively;  $p < 0.0001$  for both). LS BMD and TBS were only weakly correlated at baseline ( $r^2 = 0.04$ ) with no correlation between the changes in BMD and TBS over 24 months.

**Conclusions:** In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

**KEY WORDS:** osteoporosis, parathyroid hormone, teriparatide, bone mineral density, trabecular bone score, treatment, open-label study

## MINI ABSTRACT

Treatment effects over two years of teriparatide versus ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine BMD and trabecular bone score (TBS).

1 Teriparatide induced larger increases in BMD and TBS compared to ibandronate suggesting a  
2 more pronounced effect on bone microarchitecture of the bone anabolic drug.  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## INTRODUCTION:

Osteoporosis and osteoporosis-related fractures represent a worldwide disease burden, especially in North America and Europe [1-5]. With much of this burden stemming from the morbidity and mortality related to the roughly nine million osteoporotic fractures that occur each year [4, 5], the primary goal of treatment has long been fracture prevention [6-8].

As recommended by the *World Health Organization* (WHO) since 1994 [9], bone mineral density (BMD), measured by dual x-ray absorptiometry (DXA), is the current gold standard for diagnosing osteoporosis and monitoring treatment, supported by the fact that BMD is a major determinant of bone strength and fracture risk [10]. However, considerable overlap exists between BMD values in individuals who develop fractures and those who do not [11], indicating that other factors influence both bone strength and fracture risk. To cite just but a few: macro-geometry of cortical bone, micro-architecture of trabecular bone, as well as bone micro-damage, mineralization, and turnover [12-14].

The trabecular bone score (TBS) is derived from a simple antero-posterior LS DXA scan and can be used for the non-invasive assessment of intravertebral cancellous bone microarchitecture [15-18]. The TBS was shown to discriminate between patients with incident hip, non-vertebral or vertebral fracture and non-fractured patients with osteoporosis in several prospective and retrospective cohort studies [19-24], with odds ratios ranging between 1.6 and 2.05 with a similar order of magnitude than lumbar spine BMD [19, 21, 22, 24]. In addition, in these studies, the combination of TBS and lumbar spine BMD (LS BMD) was generally superior to either measurement alone with regard to fracture risk prediction [19, 20, 22-24]. Furthermore, the TBS was responsive to treatment with antiresorptive drugs in a large cohort study [25] and in the retrospective analysis of a randomized placebo-controlled trial with the aminobisphosphonate zoledronate [26].

Daily subcutaneous injections of recombinant human 1-34 N-terminal fragment of parathyroid hormone (teriparatide) were shown to increase BMD and to reduce the risk of new vertebral and non-vertebral, but not hip, fractures in patients with postmenopausal and glucocorticoid-induced osteoporosis [27, 28]. The observed increases in LS BMD with teriparatide accounted for approximately 30-41% of the achieved vertebral fracture risk reduction, suggesting other mechanisms accounting for the remainder [27, 29]. Teriparatide was recently shown to improve trabecular microarchitecture in iliac crest bone biopsies of postmenopausal women [29], confirming earlier preclinical data showing improved histomorphometric cancellous bone parameters and vertebral bone strength in ovariectomized rats [30] and monkeys [31]. The effects of teriparatide on the TBS are unknown.

Bisphosphonates, such as the aminobisphosphonate ibandronate (IBN), are inhibitors of bone resorption belonging to the mainstay of osteoporosis treatment. Histomorphometric data in postmenopausal women treated during two years with intravenous ibandronate showed no increase in trabecular number or volume and no decrease in inter-trabecular separation [32].

In line with these findings, an earlier study performed with the intravenous aminobisphosphonate zoledronate in postmenopausal women showed an only modest increase in TBS consistent with a preservation of vertebral bone micro-architecture [26].

The aims of this study were: (1) to compare the effects of subcutaneous teriparatide and intravenous ibandronate on LS BMD and TBS in postmenopausal women with osteoporosis; (2) to assess whether the changes in TBS are independent of those of BMD; and (3) to evaluate the changes in TBS in terms of possible clinical relevance at the individual patient level.



## MATERIALS AND METHODS:

The study was conducted at the Department of Osteoporosis of the University Hospital of Berne, Switzerland as an **open-label, retrospective, non-randomised**, treatment-controlled study comparing the **effects of an up to 2-year treatment with subcutaneous teriparatide** (Forsteo®, Eli Lilly, USA) **vs. a 2-year treatment with intravenous IBN** (Bonviva®, Roche, Switzerland) on LS BMD and TBS in two groups of postmenopausal women with osteoporosis matched for age, BMI, and LS BMD.

### *Study population and treatment schemes*

Postmenopausal women with primary osteoporosis referred for evaluation to the osteoporosis consultation of the Department of Osteoporosis of University Hospital of Berne, Switzerland, between 2007 and 2009 who were subsequently treated with teriparatide 20µg self-injected daily were **evaluated** if they had LS BMD measurements performed by DXA at baseline and after 2 years of therapy (n=70). Women treated with teriparatide usually had experienced a vertebral fragility fracture during a prior therapy with an antiresorptive, independently of their LS BMD value. **The reimbursed duration of treatment with teriparatide was increased from 18 to 24 months during the course of the study. As a consequence, one sixth of the patients treated with teriparatide were treated during 18 months followed by an intravenous infusion of zoledronate 5mg, the other five sixth were on teriparatide during 24 months.** The control group consisted of postmenopausal women with primary osteoporosis in whom a treatment with intravenous ibandronate 3mg every 3 months was initiated between 2007 and 2009 and monitored during at least two following years at the Department of Osteoporosis of Berne. Women treated with ibandronate usually had a BMD T-score at or below -2.5 or one or more prevalent vertebral fractures. Women on ibandronate were matched for age, BMI, and LS BMD with women in the teriparatide group, following a 2:1 ratio (n=140). All subjects were vitamin D-replete and received adequate calcium and vitamin D3

1 supplementation. Women currently on glucocorticoids or presenting other secondary forms of  
2 osteoporosis were not eligible. Prior therapies with bisphosphonates, estrogens, or other bone  
3 active substances, including vitamin D were allowed. **Only women with evaluable DXA**  
4 **scans for both LS BMD and TBS at baseline and after two years in the teriparatide and**  
5 **the ibandronate groups, respectively, were included in the analysis.**  
6  
7  
8  
9  
10

### 11 *Measurement of bone mineral density (BMD)*

12 Bone mineral density was assessed by DXA (Hologic QDR 4500A®, Hologic, Bedford, MA,  
13 USA) at the single study centre of the Department of Osteoporosis of the University Hospital  
14 of Berne, Switzerland. All DXA scans were performed in accordance with manufacturer  
15 recommendations. Lumbar spine BMD measurements were recorded for L1 through L4 (L1-  
16 4). BMD was expressed as grams per square centimeter of hydroxyapatite and as T-scores  
17 (standard deviation [SD] from the mean of a healthy young female population). The  
18 manufacturer's normative database was used as reference for the LS after analysis according  
19 to International Society for Clinical Densitometry (ISCD) rules [33]. Individual vertebrae  
20 were excluded in case of fractures or degenerative changes, in accordance with ISCD rules for  
21 individual vertebrae exclusion (more than 1 standard deviation from immediately adjacent  
22 vertebrae). Quality control was performed daily (anthropometric spine phantom supplied by  
23 the manufacturer).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 *Measurement of trabecular bone score (TBS)*

49 The *trabecular bone score* (TBS) is a grey-level texture measurement that can be applied to  
50 DXA images for quantifying local variations in grey level [15-17]. Using experimental  
51 variograms of 2D projection images, TBS can differentiate between 3-dimensional (3D)  
52 micro-structures that exhibit the same bone density, but different trabecular characteristics  
53 [15, 18]. The TBS is obtained by direct (re-)analysis of an acquired lumbar spine DXA image,  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

without need for further imaging. All TBS determinations were performed in a blinded manner within the Bone Disease Unit at the *University Hospital of Lausanne*, Lausanne, Switzerland using TBS iNsight® Software version 1.8.2 (Med-Imaps, Bordeaux, France). Lumbar spine TBS (LS TBS) was evaluated in the same vertebrae and regions of measurement as those used for LS BMD, with LS TBS calculated as the mean value of the individual measurements for vertebrae L1-L4. The coefficient of variation for LS BMD measurements at the Department of Osteoporosis of the University Hospital of Berne is 0.90% when applying with ISCD recommendations (15 outpatients representative of our daily routine with triplicate measurements after repositioning) with a corresponding coefficient of variation of 1.12% for TBS. Thus, the Least Significant Change (LSC) is 2.49% for LS BMD and 3.10% for TBS.

### ***Statistical analysis***

Descriptive analysis included means and percentages with standard deviations. The percent changes in BMD and TBS were calculated for each subject as the absolute change from baseline to two-year follow-up, divided by the baseline value. Bivariate inter-group comparisons were performed between those treated with IBN vs. teriparatide using Student's t-tests and Pearson  $\chi^2$  analysis for continuous and non-continuous variables, respectively. Pearson correlation coefficients were calculated for BMD vs. TBS and for change from baseline in BMD vs. change from baseline in TBS. All inferential tests were two-tailed and  $p < 0.05$  was set as the threshold for statistical significance. All statistical analyses were performed using Stata® software (Version 12, StataCorp LP., Texas, USA).

## **RESULTS**

Overall, 65 (93%) and 122 (87%) patients with evaluable DXA scans for LS BMD and TBS at baseline and after two years in the teriparatide and the ibandronate groups, respectively,

1 were included in the analysis. In total, 40%, 40%, and 20% of the patients had 4, 3, and 2  
2 vertebrae evaluated, respectively. As a result of matching, baseline characteristics (mean  $\pm$   
3 SD) were similar between groups in term of age, body mass index, baseline LS BMD T-score  
4 and LS TBS (Table 1). Patients in the teriparatide group were more likely having had prior  
5 therapy with a bisphosphonate (95.4% vs. 80.3%,  $p=0.005$ ), having prevalent vertebral  
6 fractures or a positive history of fracture during adulthood (90.5% vs. 44.3% and 73.8% vs.  
7 41.0%, respectively;  $p=0.0001$  for both), and had a significantly higher clinical fracture risk  
8 score for hip and major osteoporotic fractures assessed by FRAX®.

19 As shown in figure 1, after 24 months of therapy, LS BMD and TBS increased significantly  
20 more with teriparatide compared to IBN ( $+7.6\% \pm 6.3$  vs.  $+2.9\% \pm 3.3$  and  $+4.3\% \pm 6.6$  vs.  
21  $+0.3\% \pm 4.1$ , respectively;  $p < 0.0001$  for both). Compared to baseline, increases in LS BMD  
22 were significant in both the teriparatide and IBN group ( $p < 0.0001$  for both) while increases in  
23 LS TBS were significant in the teriparatide group only ( $p < 0.0001$ ).

31 Baseline spine BMD and TBS were only weakly correlated, ( $r^2 = 0.04$ ), indicating that only  
32 4% of the variance in one parameter was explained by the other. There was no correlation  
33 between the 2-year changes in BMD and TBS from baseline ( $r^2 = 0.01$ ).

39 As shown in table 2, LS BMD was more sensitive than LS TBS with regard to the proportion  
40 of patients achieving an increase above least significant change (LSC) in both treatment  
41 groups: 78.5% vs. 61.5% (McNemar-test  $p < 0.01$ ) and 51.6% vs. 26.3% ( $p < 0.001$ ) with  
42 teriparatide and IBN, respectively. Interestingly, while only 11.0% of the patients did not  
43 respond in terms of TBS below the LSC with teriparatide, this proportion reached 27.0% with  
44 IBN. Furthermore, in the teriparatide group, 51.0% of the patients were above the LSC for  
45 both LS BMD and TBS vs. only 28.0% in the IBN group (results not shown in table 2),  
46 suggesting a stronger effect on bone micro-architecture with the former than with the latter.

## 61 DISCUSSION

1 In postmenopausal women with primary osteoporosis, a 2-year treatment with teriparatide  
2 increased LS BMD and TBS significantly more and in a significantly greater proportion of  
3 patients than a 2-year treatment with intravenous ibandronate. As the increase in LS TBS was  
4 largely independent from the BMD response, these results suggests that LS TBS may  
5 contribute to assess the effects of bone anabolic agents on vertebral micro-architecture.  
6  
7  
8  
9  
10

11  
12  
13  
14 Only few studies have investigated the effect of bone active substances on LS TBS [25, 26].  
15  
16 Taken together with the present findings, these earlier reports are consistent with the concept  
17 that bisphosphonates allow for “positive maintenance” of bone micro-architecture rather than  
18 a major improvement in micro-architecture. For almost two decades, bisphosphonates have  
19 been the therapy of choice to treat osteoporosis and to prevent fractures, relying on solid  
20 evidence with regard to fracture risk reduction [2, 34-38]. However, the long-term bone safety  
21 of bisphosphonates has been recently questioned [39]. On one hand, bisphosphonates increase  
22 bone strength by increasing the mineralization of remodelled bone units, reducing cortical  
23 porosity and decreasing focal stress. On the other hand, they suppress the generation of new  
24 bone remodelling units and reduce bone turnover [39]. In the present study, the increase in LS  
25 BMD and TBS observed with IBN was of a lower order of magnitude than expected. In  
26 earlier studies, LS TBS increased by 0.25 to 0.5% per year under antiresorptive therapy [25,  
27 26], which is clearly more than the 0.3% over two years reported in the present study. One of  
28 the possible explanations may be related to the fact that more than 80% of the “real life”  
29 women included had been on bisphosphonate therapy before being switched to intravenous  
30 ibandronate after a very short or no washout period. This suggests not unexpectedly that, in  
31 patients under prior antiresorptive therapy, bisphosphonates may be more likely to maintain  
32 than to restore vertebral microarchitecture.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Teriparatide exerts primarily bone anabolic effects, which include increasing cancellous bone  
2 volume and connectivity, increasing cortical bone thickness, and enhancing trabecular  
3 morphology [39, 40]. Since the inaugural publication by Neer *et al* in 2001 [27], several  
4 smaller studies have confirmed that teriparatide allows for strong BMD increases and for  
5 fracture risk reduction, suggesting that it may become an attractive alternative to  
6 bisphosphonates for strengthening and possibly restoring bone microarchitecture [41-44]. In  
7 the present study, a 2-year therapy with subcutaneous teriparatide induced a statistically  
8 significant increase in LS BMD and TBS of large magnitude. The latter (+4.3% in only two  
9 years) exceeds by far the TBS increases reported with antiresorptive substances to date [25,  
10 26]. Furthermore, the ratio of BMD to TBS increase was approximately 2:1 with teriparatide  
11 and 9:1 with ibandronate in the present study, compared to 10:1 with bisphosphonates in a  
12 retrospective study of 534 postmenopausal women treated with antiresorptive therapy in the  
13 Canadian province of Manitoba [25], and 4:1 in a 3-year randomized controlled study with  
14 yearly intravenous zoledronate [26]. Taken together with the absence of a significant  
15 correlation between changes from baseline in BMD and changes from baseline in TBS [25,  
16 26], these observations indicate that BMD and TBS measure different characteristics of bone  
17 and bone strength.

18  
19 With regard to individual therapy monitoring, only 12-35% of patients on bisphosphonates  
20 had an increase in TBS that was exceeding the LSC in earlier studies [25, 26], as compared to  
21 26% in the present analysis. In contrast, about 62% of the patients on teriparatide were above  
22 LSC, primarily indicating that LS TBS may be more suitable for monitoring the effects of  
23 bone anabolic substances than for monitoring the effects of antiresorptives.

24  
25 To date, only one direct comparison between teriparatide and a bisphosphonate (risedronate)  
26 has been published in postmenopausal women with osteoporotic spine compression fractures.

1 In that study, teriparatide yielded a significantly greater increase in BMD from baseline in the  
2 lumbar spine and femoral neck, and was associated with a lower incidence of vertebral  
3 fractures at 18 months (4% versus 9%, respectively;  $p = 0.01$ ) and with less severe  
4 vertebral fractures ( $p = 0.04$ ) [45]. There have, on the other hand, been several studies  
5 assessing the effects of teriparatide in patients in whom bisphosphonate treatment has failed  
6 or otherwise been terminated. In the most recently-published study, post-menopausal women  
7 with severe osteoporosis who had failed treatment with a bisphosphonate responded well to  
8 18 months of treatment with daily parathyroid hormone, with a 37% reduction in the  
9 incidence of fractures in their second year of treatment relative to their first 6 months of  
10 therapy, and a 76% reduction relative to baseline subsequent to this. Patients also reported  
11 reduced back pain and improved health-related quality of life while taking teriparatide [46].  
12 These results are consistent with the results of several prior studies demonstrating some  
13 benefit of parathyroid hormones in the aftermath of bisphosphonate therapy [41, 44, 47]  
14 although it is the first time that results are reported with TBS.  
15

16 The findings of the present study are limited by the retrospective nature of the analysis.  
17 Pretreatment with antiresorptives may have partially blunted some of the expected effects on  
18 LS BMD and TBS. In addition, the two groups were not comparable with respect to  
19 osteoporosis severity, which may have influenced the results. Keeping these limitations in  
20 mind, the results show for the first time that larger effects on trabecular microarchitecture  
21 assessed by TBS may be expected when using bone anabolic substances and may open the  
22 way for future research in this direction including, but not limited to, the place of TBS alone  
23 and/or in combination with BMD and/or clinical risk factors for the choice and monitoring of  
24 treatments with bone active substances and the identification of more individualized treatment  
25 schemes for patients with osteoporosis at increased risk of fracture.  
26

## 27 CONCLUSIONS

1 In women with postmenopausal osteoporosis, a 2-year treatment with teriparatide exerted  
2 more beneficial effects on lumbar spine BMD and microarchitecture assessed by TBS than  
3 ibandronate. Changes in LS BMD and TBS from baseline were not correlated, confirming that  
4 these two parameters measure different responses of bone to therapy. At the individual patient  
5 level, TBS was significantly more sensitive to bone anabolic substances than to  
6 antiresorptives, with almost two thirds of the patients on teriparatide showing TBS increases  
7 above the least significant change.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**Figure legends**

**Figure 1**

**Percent change in lumbar spine BMD and TBS at month 24 after treatment with teriparatide (22.9 months) and ibandronate (24 months).**

**Mean values  $\pm$  standard deviation**

**p values above the bars refer to significance vs. baseline.**

## Disclosures

Didier Hans is co-owner of the TBS patent and has corresponding ownership shares.

**Christoph Senn, Beatrice Günther, Albrecht W. Popp, Romain Perrelet and Kurt**

**Lippuner declare that they have no conflict of interest.**

## Acknowledgements

We are grateful to Philippe Kress, MD, for reviewing and commenting on our manuscript.

## References

1. Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. *Ortop Traumatol Rehabil* 9:337-356
2. Cooper C, Reginster JY, Cortet B, Diaz-Curiel M, Lorenc RS, Kanis JA, Rizzoli R (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). *Curr Med Res Opin* 28:475-491
3. Dhanwal DK, Dennison EM, Harvey NC, Cooper C (2011) Epidemiology of hip fracture: Worldwide geographic variation. *Indian J Orthop* 45:15-22
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res* 22:465-475
5. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17:1726-1733
6. (2001) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. *South Med J* 94:569-573
7. (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. *Arthritis Rheum* 44:1496-1503
8. Tucci JR (2006) Importance of early diagnosis and treatment of osteoporosis to prevent fractures. *Am J Manag Care* 12:S181-190
9. (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 843:1-129
10. Johnell O, Kanis JA, Oden A, et al. (2005) Predictive value of BMD for hip and other fractures. *J Bone Miner Res* 20:1185-1194
11. Hordon LD, Raisi M, Aaron JE, Paxton SK, Beneton M, Kanis JA (2000) Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. Two-dimensional histology. *Bone* 27:271-276
12. Link TM, Majumdar S (2004) Current diagnostic techniques in the evaluation of bone architecture. *Curr Osteoporos Rep* 2:47-52
13. Rubin CD (2005) Emerging concepts in osteoporosis and bone strength. *Curr Med Res Opin* 21:1049-1056
14. Dalle Carbonare L, Giannini S (2004) Bone microarchitecture as an important determinant of bone strength. *J Endocrinol Invest* 27:99-105
15. Hans D, Barthe N, Boutroy S, Pothuau L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. *J Clin Densitom* 14:302-312
16. Pothuau L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D (2009) Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. *J Clin Densitom* 12:170-176
17. Pothuau L, Carceller P, Hans D (2008) Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. *Bone* 42:775-787

18. Silva BC, Boutroy S, Zhang C, et al. (2013) Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab* 98:1963-1970
19. Del Rio LM, Winzenrieth R, Cormier C, Di Gregorio S (2013) Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study. *Osteoporos Int* 24:991-998
20. Krueger D, Fidler E, Libber J, Aubry-Rozier B, Hans D, Binkley N (2013) Spine Trabecular Bone Score Subsequent to Bone Mineral Density Improves Fracture Discrimination in Women. doi: 10.1016/j.jocd.2013.05.001. *J Clin Densitom*
21. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R (2013) Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. *Osteoporos Int* 24:77-85
22. Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, Kagamimori S, Kagawa Y, Yoneshima H (2013) Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese population-based osteoporosis (JPOS) cohort study. *J Bone Miner Res*
23. Briot K, Paternotte S, Kolta S, Eastell R, Reid DM, Felsenberg D, Gluer CC, Roux C (2013) Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. *Bone* 57:232-236
24. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. *J Bone Miner Res* 26:2762-2769
25. Krieg MA, Aubry-Rozier B, Hans D, Leslie WD, Manitoba Bone Density P (2013) Effects of anti-resorptive agents on trabecular bone score (TBS) in older women. *Osteoporos Int* 24:1073-1078
26. Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D, Lippuner K (2013) Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. *J Bone Miner Res* 28:449-454
27. Neer RM, Arnaud CD, Zanchetta JR, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 344:1434-1441
28. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 357:2028-2039
29. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. *J Bone Miner Res* 22:1173-1180
30. Arita S, Ikeda S, Sakai A, Okimoto N, Akahoshi S, Nagashima M, Nishida A, Ito M, Nakamura T (2004) Human parathyroid hormone (1-34) increases mass and structure of the cortical shell, with resultant increase in lumbar bone strength, in ovariectomized rats. *J Bone Miner Metab* 22:530-540
31. Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A, Sato M (2007) Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. *J Bone Miner Res* 22:841-848
32. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanaukaite D, Rowell L, Felsenberg D (2010) Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. *Bone* 46:660-665

33. Hans D, Downs RW, Jr., Duboeuf F, Greenspan S, Jankowski LG, Kiebzak GM, Petak SM (2006) Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. *J Clin Densitom* 9:15-21
34. Black DM, Delmas PD, Eastell R, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med* 356:1809-1822
35. Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. *Osteoporos Int* 23:2329-2333
36. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. *J Clin Endocrinol Metab* 84:3076-3081
37. Rakel A, Boucher A, Ste-Marie LG (2011) Role of zoledronic acid in the prevention and treatment of osteoporosis. *Clin Interv Aging* 6:89-99
38. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res* 15:1006-1013
39. Seeman E, Delmas PD (2006) Bone quality--the material and structural basis of bone strength and fragility. *N Engl J Med* 354:2250-2261
40. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. *J Bone Miner Res* 18:1932-1941
41. Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S (2011) Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months. *Calcif Tissue Int* 89:130-139
42. Fahrleitner-Pammer A, Langdahl BL, Marin F, et al. (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). *Osteoporos Int* 22:2709-2719
43. Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Juppner H, Neer RM (2009) Effects of teriparatide retreatment in osteoporotic men and women. *J Clin Endocrinol Metab* 94:2495-2501
44. Trevisani VF, Riera R, Imoto AM, Saconato H, Atallah AN (2008) Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review. *Sao Paulo medical journal = Revista paulista de medicina* 126:279-284
45. Hadji P, Zanchetta JR, Russo L, et al. (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. *Osteoporos Int* 23:2141-2150
46. Jakob F, Oertel H, Langdahl B, et al. (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. *Eur J Endocrinol* 166:87-97
47. Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C (2010) Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. *J Bone Miner Metab* 28:68-76

**Table 1: Baseline Demographics and Clinical Characteristics (mean  $\pm$  SD)**

	Teriparatide Group	IBN Group	P value
N	65	122	
Duration of <b>active treatment</b> (months)	22.9 $\pm$ 3.6	24.0 $\pm$ 4.7	0.10
Age (years)	68.9 $\pm$ 9.0	67.4 $\pm$ 6.5	0.20
BMI (kg/m <sup>2</sup> )	23.7 $\pm$ 4.2	23.8 $\pm$ 3.5	0.92
Prior therapy with an oral / IV bisphosphonate (%)	95.4	80.3	0.005
Duration of washout prior to study drug initiation (months)	0.23 $\pm$ 0.79	0.26 $\pm$ 0.85	0.23
Lumbar spine			
BMD (g/cm <sup>2</sup> )	0.759 $\pm$ 0.153	0.732 $\pm$ 0.080	0.12
T-score	-2.66 $\pm$ 1.35	-2.77 $\pm$ 0.67	0.46
TBS	1.206 $\pm$ 0.100	1.209 $\pm$ 0.100	0.85
Total hip			
BMD (g/cm <sup>2</sup> )	0.703 $\pm$ 0.113	0.729 $\pm$ 0.100	0.10
T-score	-1.96 $\pm$ 0.93	-1.75 $\pm$ 0.78	0.11
Femoral neck			
BMD (g/cm <sup>2</sup> )	0.606 $\pm$ 0.105	0.622 $\pm$ 0.084	0.27
T-score	-2.09 $\pm$ 1.17	-2.11 $\pm$ 0.81	0.91
Prevalent vertebral fractures (%)	90.5	44.3	0.0001
Positive history of non-vertebral fractures during adulthood (%)	73.8	41	0.0001
Past use of glucocorticosteroids (%)	9%	4.6%	0.28
10-year absolute risk for major osteoporotic fractures (FRAX® with BMD, %)	26.7 $\pm$ 10.4	21.1 $\pm$ 10.1	0.0001
10-year absolute risk for hip fractures (FRAX® with BMD, %)	8.15 $\pm$ 6.7	5.1 $\pm$ 5.1	0.0001


All values are means  $\pm$  SD, except indicated otherwise

**Table 2: Percentage of patients above, within and below the least significant change (LSC) for both teriparatide and IBN groups and for lumbar spine (LS) BMD and TBS**

	<b>Above LSC (%)</b>	<b>Within LSC (%)</b>	<b>Below LSC (%)</b>
Teriparatide			
LS BMD	78.5	20.0	1.5
LS TBS	61.5	27.7	10.8
Ibandronate			
LS BMD	51.6	42.6	5.8
LS TBS	26.3	46.7	27.0

**Within LSC for LS BMD is between -2.49% and +2.49%**

**Within LSC for LS TBS is between -3.10% and +3.10%**





# OSTEOPOROSIS INTERNATIONAL

## Authorship & Disclosure Form



COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS)

**Article Title (first few words)**

**First Author:** Senn C  
**E-mail:** christoph.senn@insel.ch

After submission of this agreement signed by all authors, changes of authorship or in the order of the authors listed will not be accepted by Springer.

### AUTHORSHIP

I, the undersigned author(s), certify that:

- I have seen and approved the final version of the manuscript, and all subsequent versions.
- I have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
- I have drafted the article or revised it critically for important intellectual content.

I accept public responsibility for it, and believe it represents valid work. As an author of this article, I also certify that none of the material in the manuscript has been previously published, nor is it included in any other manuscript. I certify that this manuscript is not under consideration for publication elsewhere, nor has it been submitted or accepted in another publication in any form. The rights or interest in the manuscript have not been assigned to any third party.

Moreover, should the editor of *Osteoporosis International* request the data upon which the manuscript is based, I shall produce it. I also certify that I have read and complied with the copyright information, as found on the *Osteoporosis International* home page website.

### FINANCIAL DISCLOSURE/CONFLICT OF INTEREST

I certify that any financial interests such as employment, stock ownership, honoraria, paid expert testimony, as well as any personal relationships, academic competition, and intellectual passion which may inappropriately influence my actions, have been disclosed on a separate attachment.

All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged in a footnote.

I have had full access to all the data in the study (if applicable) and thereby accept full responsibility for the integrity of the data and the accuracy of the data analysis.

By checking the box next to my signature I assert that there are no conflicts of interest (both personal and institutional) regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.

### PLEASE NOTE

1. **Every author must sign the Authorship & Disclosure form.**
2. **It is possible to submit more than one form if the authors are in several locations.**
3. **All forms must be submitted at the same time.**
4. **Completed forms must be scanned and included as a pdf file during the online submission process as a supplemental file not for review.**

**Please email any queries to the appropriate Managing Editor:**

European Office: Fina Liu – [oi.europe@iofbonehealth.org](mailto:oi.europe@iofbonehealth.org)

USA Office: Adrienne Tewksbury – [tewksburya@helenhayeshosp.org](mailto:tewksburya@helenhayeshosp.org)

# OSTEOPOROSIS INTERNATIONAL Authorship & Disclosure Form



MANUSCRIPT ID NUMBER (IF KNOWN)

☒ Gerr  
Author's signature

Christoph Seny  
Printed name and date  
20-Nov-2013

☒ B. Gunther  
Author's signature

Beatrice Gunther  
Printed name and date  
20. NOV 2013

☒ A. Popp  
Author's signature

Albrecht W Popp  
Printed name and date  
20 NOV 2013

☒ R. Perrelet  
Author's signature

Romain Perrelet  
Printed name and date  
21 NOV 2013

☒ D. Hauss  
Author's signature

Didier Hauss  
Printed name and date  
20 NOV 2013

☒ Lippuner K.  
Author's signature

Lippuner K., 20-Nov-2013  
Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date

☐ \_\_\_\_\_  
Author's signature

Printed name and date